Ignite Creation Date:
2025-12-24 @ 5:55 PM
Ignite Modification Date:
2026-02-23 @ 12:21 PM
Study NCT ID:
NCT00382668
Status:
COMPLETED
Last Update Posted:
2011-04-14
First Post:
2006-09-26
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study of Dasatinib to See How Liver Impaired and Healthy Subjects Process and React to the Study Drug
Sponsor:
Bristol-Myers Squibb
Organization:
Study Overview
Official Title:
Single-Dose Pharmacokinetics of Dasatinib in Subjects With Hepatic Impairment Compared to Healthy Adult Subjects
Status:
COMPLETED
Status Verified Date:
2011-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary purpose of this study is to evaluate how a person with liver impairment processes and reacts to the study drug. Information about any side effects that may occur will also be collected.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: